Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy.

Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J, Kuntze J, Blizzard RM, Cara JF, Chernausek SD

The Journal of pediatrics1 Aug 1993Cited by 65 (Europe PMC)

PMID8345416DOI10.1016/s0022-3476(05)81691-9PepBankPUB-08345416

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with idiopathic short stature, daily somatotropin dosing produced growth of 9.0 versus 7.8 cm/yr with three-times-weekly dosing (p = 0.0005).
In plain wordsIn children with idiopathic short stature, daily somatotropin dosing produced faster growth than three-times-weekly dosing.
Peptide
HGH (somatotropin)
Outcome
IncreaseGrowth rate by dosing frequency
Study
n: not reported in source
Comparator
Three-times-weekly dosing
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneouslyAs given in this study (human).
Measurements
Growth rate
9 cm/yr
daily dosing
Growth rate
7.8 cm/yr
three-times-weekly dosing
Source sentences
Summary
Daily dosing resulted in a significantly faster mean growth rate (9.0 cm/yr) than three-times-weekly dosing (7.8 cm/yr) (p = 0.0005).
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541602
02HumanRandomized controlled trialEfficacy outcome
In children with idiopathic short stature, mean second-year growth was 7.6 cm/yr and did not differ by somatotropin dosing group.
In plain wordsIn children with idiopathic short stature, second-year growth did not differ between somatotropin dosing groups.
Peptide
HGH (somatotropin)
Outcome
No significant changeSecond-year growth rate by dosing group
Study
n: not reported in source
Comparator
Other dosing-frequency group
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneously · Year 2As given in this study (human).
Measurements
Mean growth rate
7.6 cm/yr
year 2
Source sentences
Summary
Mean growth rates were 7.6 and 7.2 cm/yr during years 2 and 3, respectively, and did not differ by dosing group.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541603
03HumanRandomized controlled trialEfficacy outcome
In children with idiopathic short stature, mean third-year growth was 7.2 cm/yr and did not differ by somatotropin dosing group.
In plain wordsIn children with idiopathic short stature, third-year growth did not differ between somatotropin dosing groups.
Peptide
HGH (somatotropin)
Outcome
No significant changeThird-year growth rate by dosing group
Study
n: not reported in source
Comparator
Other dosing-frequency group
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneously · Year 3As given in this study (human).
Measurements
Mean growth rate
7.2 cm/yr
year 3
Source sentences
Summary
Mean growth rates were 7.6 and 7.2 cm/yr during years 2 and 3, respectively, and did not differ by dosing group.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541604
04HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature completing treatment, growth rate increased from 4.6 to 8.0 cm/yr in the first treatment year.
In plain wordsIn children with idiopathic short stature completing treatment, growth was faster during the first somatotropin year than before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFirst-year growth rate versus pretreatment
Study
n = 92
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneously · First yearAs given in this study (human).
Measurements
Growth rate
4.6 cm/yr
pretreatment
Growth rate
8 cm/yr
first treatment year
Source sentences
Summary
For the 92 subjects who completed 36 months of treatment, mean growth rate increased from a mean of 4.6 cm/yr before treatment to a mean of 8.0 cm/yr in the first year of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541601
05HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature, mean standardized height improved from -2.7 to -1.6 during somatotropin therapy.
In plain wordsIn children with idiopathic short stature, standardized height improved during somatotropin treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseStandardized height
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneously · 3 yearsAs given in this study (human).
Measurements
Standardized height
−2.7 score
before treatment
Standardized height
−1.6 score
after 3 years
Source sentences
Summary
Mean standardized height for all subjects improved from -2.7 to -1.6 after 3 years.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541605
06HumanNon-randomized trialEfficacy outcome
In children with idiopathic short stature receiving somatotropin, predicted adult height SD score increased from -2.7 to -1.6 independently of pubertal onset timing.
In plain wordsIn children with idiopathic short stature, predicted adult height improved during somatotropin treatment, regardless of when puberty started.
Peptide
HGH (somatotropin)
Outcome
IncreasePredicted adult height SD score
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneously · 3 yearsAs given in this study (human).
Measurements
Predicted adult height SD score
−2.7 score
before treatment
Predicted adult height SD score
−1.6 score
after treatment
Source sentences
Summary
Mean standardized Bayley-Pinneau predicted adult height SD score increased from -2.7 to -1.6 and was independent of the timing of pubertal onset, but for individuals this score was more variable.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541607
07HumanObservational studyEfficacy outcome
In somatotropin-treated children, those remaining prepubertal gained more bone-age-standardized height than those becoming pubertal (p < 0.02).
In plain wordsIn somatotropin-treated children, remaining prepubertal was linked to larger bone-age-adjusted height gains than becoming pubertal.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone-age-standardized height gain by pubertal status
Study
n: not reported in source
Comparator
Children who became pubertal
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneously · 3 yearsAs given in this study (human).
Source sentences
Summary
When the growth rate was standardized for bone age, however, subjects who remained prepubertal had a significantly greater gain in mean height SD score than subjects who became pubertal during that 3-year period (p < 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541606
08HumanObservational studyEfficacy outcome
In somatotropin-treated children with idiopathic short stature, first-year growth response best predicted growth in subsequent years.
In plain wordsIn somatotropin-treated children with idiopathic short stature, first-year growth response was linked to later growth.
Peptide
HGH (somatotropin)
Outcome
Not applicableEarly response as predictor of subsequent growth
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneouslyAs given in this study (human).
Source sentences
Summary
Year-1 growth response, expressed as growth rate or change in height SD score, was the best predictor of growth in subsequent years.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541608
09HumanObservational studyEfficacy outcome
In children with idiopathic short stature, baseline anthropometry, IGF-I SD score and GH levels did not reliably predict somatotropin treatment response.
In plain wordsIn children with idiopathic short stature, baseline body measurements and hormone levels did not reliably predict somatotropin treatment response.
Peptide
HGH (somatotropin)
Outcome
Not applicableBaseline variables as predictors of treatment response
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
0.3 mg/kg per week · subcutaneouslyAs given in this study (human).
Source sentences
Summary
Responses to therapy could not be reliably predicted from baseline anthropometric variables, plasma insulin-like growth factor I SD score, growth hormone levels.
2 context sentences(design, population, supporting numbers)
Summary · context
For year 1 of the study, 121 prepubertal children were randomly selected to receive somatotropin, 0.3 mg/kg per week, administered subcutaneously three times weekly (n = 63), or to be nontreatment control subjects (n = 58).
Summary · context
After 1 year, all subjects were again randomly selected to receive either three-times-weekly or daily dosing at the same total dose.
Report a problemFND-0834541609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.